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The sentinel node is the first lymph node to receive lymphatic drainage from a tumour and is usually the first site of metastases.
Today, the sentinel node is used for tumour staging. Here, we focus on its immunological role and investigate lymphocytic function in
sentinel nodes, identified intraoperatively by peritumoural dye injection, from 15 patients with colon cancer. Tumour infiltrating
lymphocytes, sentinel and nonsentinel lymph node cells and peripheral blood leukocytes were studied by flow cytometry,
proliferation assays and interferon-g secretion after activation with autologous tumour homogenate. Whereas tumour-infiltrating
lymphocytes were nonresponsive in the proliferation assays, lymphocytes from sentinel nodes proliferated dose dependently and
secreted interferon-g upon stimulation with tumour homogenate. The responses were of varying magnitude and tended to be
weaker in metastatic sentinel nodes. Sentinel node lymphocytes represents an enriched source of tumour reactive lymphocytes, and
may be useful in future trials of adoptive immunotherapy.
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Colorectal cancer (CRC) is a major cause of morbidity worldwide,
accounting for over 1 million new cases and 500000 deaths per
year (Parkin et al, 2005). Surgery is the primary treatment
modality and is curative in approximately 50% of patients,
however, the remaining half of patients will ultimately die of
metastatic disease (Obrand and Gordon, 1997). Standard, Fluoro-
uracil-based, chemotherapy in the adjuvant setting confers at most
10% absolute increase in survival in patients with lymph node
positive disease (Duke’s C) (Arkenau et al, 2003), while there is no
evidence for its benefit in patients with localised disease (Benson
et al, 2004). Thus, there is a great need for developing alternative
adjuvant treatments.
Studies of prognostic factors in colorectal cancer point out the
histological status of the regional lymph nodes as the most
important predictor of survival (Swanson et al, 2003) and the
presence of regional lymph node metastases implies a 40–50%
reduction in 5-year survival rates. The sentinel node is defined as
the first lymph node, or nodes, to receive lymphatic drainage from
a tumour. It can be identified during surgery by injection of a
tracer substance around the tumour. The tracer is transported in
the lymph capillaries and accumulates in the sentinel node(s), thus
identifying the tumour draining lymph node. The histological
status of the sentinel node is regarded as representative for the
status of the entire lymphatic field. The sentinel node method, first
introduced in 1977 (Cabanas, 1977), is established in malignant
melanoma and breast cancer (Leong, 2004) and it has also been
applied to colon cancer (Saha et al, 2000; Tho ¨rn, 2000). Recently,
we demonstrated the usefulness of sentinel node detection for the
staging of colon cancer (Dahl et al, 2005).
According to the immune surveillance hypothesis (Burnet,
1970), the immune system is continuously sensitised against
developing tumours, most of which are eliminated at an early
stage. Strong experimental evidence in favour of this notion has
been presented in recent years, extensively reviewed by Dunn et al
(2004). The identification of specific tumour antigens has created
new possibilities for tumour immunotherapy (Rosenberg, 2001)
and many immunotherapeutic approaches are now being trans-
lated into clinical trials (Ribas et al, 2003). Among these, adoptive
transfer of tumour antigen-specific lymphocytes seems particularly
promising. These attempts are usually based on either mono-
nuclear cells from peripheral blood or tumour infiltrating
lymphocytes (TIL) separated from fresh tumour specimens. In
recent trials, treatment of patients with malignant melanoma with
autologous transfer of expanded TILs, objective response rates of
up to 51% has been reported (Rosenberg and Dudley, 2004). In
CRC, the presence of TIL correlates with a more favourable
prognosis (Giorgio et al, 1992) and TIL from CRCs, expanded in
vitro in IL-2, display specific cytokine secretion in response to
autologous tumour cells (Hom et al, 1993). However, TIL from
several human tumours, including CRC, display reduced levels of
the CD3 zeta chain (Nakagomi et al, 1993). In addition, T-cell
responses to mitogenic stimulation are decreased in lymphocytes
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sfrom the venous blood draining CRCs, as compared with
lymphocytes obtained from the arterial blood supplying the
tumour (Rigg et al, 1991). Thus, the limited number of TIL that
can be obtained from solid tumour biopsies may not be an ideal
cell population for adoptive immunotherapy.
As experimental evidence indicate that activation of naı ¨ve T cells
occurs within the highly specialised microenvironment of second-
ary lymphoid organs, that is lymph nodes and spleen (Itano and
Jenkins, 2003), the sentinel node may be regarded as the primary
site for the immune system to encounter tumour antigens. In the
present study, we take advantage of the specific sentinel node
detection to investigate the immunological tumour reactivity in
sentinel lymph nodes draining human colon cancers.
MATERIALS AND METHODS
Patients
Fifteen patients with colon cancer, with no signs of distant
metastases or lymph node involvement prior to surgery, seven
men and eight women, with an average age of 71 years were
included in the study (Table 1). The study was approved by the
local ethical committee and informed consent was given by the
patients.
Identification of sentinel nodes
The colonic tumour site was mobilised through division of
peritoneal adhesions to facilitate inspection of tumour and
mesentery. One ml Patent blue dye (Guerbet, Paris) was injected
superficially in the serosa around the tumour. Within 5min, one to
four blue-coloured mesenteric lymph nodes were identified
macroscopically as sentinel nodes and they were marked with
sutures.
Preparation of specimens
The sentinel and nonsentinel nodes were cut in half. Slices o1mm
thick were cut from the central and the peripheral part of the nodes
for flow cytometry and proliferation analysis. The rest of the node
underwent routine histopathological examination. Tumours were
histopathologically classified as Duke’s stages A–D (Duke, 1932)
(Table 1). One piece of the primary tumour (including part of the
invasive margin) was removed for flow cytometry analyses and as
an antigen source.
Flow cytometry analyses
Peripheral blood leukocytes (PBL), lymph node cells and tumour
cell suspensions at 1 10
6cellssample
 1 were subjected to
investigation using flow cytometry (FACS). Cells were washed in
PBS containing 2% FCS and 0.05% NaN3 and stained with
fluorophore conjugated antibodies against the cell surface
molecules CD4 PE, CD8 PerCp (Becton Dickinson, San Jose, CA,
USA) and the very early activation marker CD69 FITC (Pharmin-
gen, San Jose, CA, USA). After staining, cells were investigated
using a FACSCalibur (Becton Dickinson) and data were analysed
using the Cellquest computer software (Becton Dickinson).
Immunological evaluation
Single cell suspensions from lymph nodes and tumours were
obtained by gentle pressure using a loose fit glass homogeniser.
Peripheral blood leukocytes were purified by ficoll-paque (Phar-
macia, Amersham, Uppsala, Sweden). Cells were resuspended and
washed twice in RPMI 1640 (Life technologies, Rockville, MD,
USA) containing 2.5% fetal calf serum (FCS) (Life technologies).
Finally, cells were resuspended in RPMI 1640 proliferation media
containing 10% human AB serum (Sigma-Aldrich, St Louis, MO,
USA), 1% penicillin–streptomycin (Sigma) and 1% glutamine
(Sigma). Tumour samples were homogenised using a Ultra-turrax
in 5v (wv
 1)o f2  PBS followed by 5min denaturation at 971C.
Tumour homogenates were diluted to 1:10 and 1:100 in complete
proliferation media. Purified PBL and lymph node cells were used
at 3 10
5cellswell
 1 in time course proliferation assays against
diluted tumour homogenate, Con A 10mgml
 1 (Sigma) or
carcinoembryonic antigen 100mgml
 1 (Sigma) in triplicate.
Proliferation was measured by adding 1mCi of
3H-Thymidine/well
(Amersham) 18h prior to harvesting. Samples were subjected to
scintillation counting.
Stimulations for the measurement of IFN-g secretion were
performed in 96-well plates with 3 10
5cellswell
 1 in triplicate
with tumour homogenate diluted 1/10 and 1/100, or Con A
10mgml
 1 (Sigma). The amount of secreted IFN-g was measured
with ELISA (Human IFN-g Duoset, R&D Systems) on culture
supernatants in pooled samples of the triplicates.
Table 1 Patient characteristics, location of tumours, staging and investigated lymph nodes
Patient No Sex Age (year) Tumour site
Duke’s
classification
Metastatic
nodes/harvest
nodes
No of SNs
obtained
Number of cells
in SN ( 106) %CD4/%CD8
a
1 M 80 Sigmoid B 0/18 1 27 44/6
2 M 81 Ascending B 0/22 1 63 52/7
3 F 58 Ascending B 0/29 1 MI 41/7
4 F 80 Ascending B 0/5 2 29 65/4
5 M 82 Ascending B 0/12 4 14 55/14
6 M 66 Descending B 0/22 3 66 47/5
7 F 73 Transversum B 0/23 4 26 58/7
8 M 66 Caecum B 0/19 2 159 35/6
9 M 71 Descending B 0/25 3 121 43/10
10 M 70 Sigmoid C 1/14 2 33 55/8
11 F 78 Ascending C 2/19 2 11 27/58
12 F 75 Ascending C 4/23 2 36 37/ND
13 F 63 Sigmoid C 6/20 3 170 41/7
14 F 57 Sigmoid C 1/17 2 278 41/14
15 F 61 Sigmoid D 1/13 3 30 34/6
MI¼Missing information. ND¼Not done.
aAverage percentage of CD4
+ and CD8
+ cells in gated SN lymphocytes measured by flow cytometry. Lymphocytes were defined by
gating on forward and side scatter characteristics.
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Intraoperative identification of sentinel node and
pathological classification
One to four sentinel nodes (average 2.3) were detected intra-
operatively using Patent blue injection in the circumference of the
tumour. Patient characteristics and location of the tumours are
presented in Table 1. Upon macroscopical dissection of the
removed specimens, between five and 29 lymph nodes (average 19)
were identified and embedded for histopathological evaluation
(Figure 1A and B, left panels). Nine of the patients (Table 1)
showed no signs of metastatic spread to sentinel node(s), nor to
other lymph nodes despite that tumours grew through the bowel
muscular wall (Figure 1A left panel) and they were classified as
Duke’s B. Patients no 10–14 (Table 1) had metastatic spread to the
sentinel node and were histopathologically classified as Duke’s C
(Figure 1B left panel). Between one and six metastatic lymph nodes
were identified by histopathology (Table 1). Patient no 15 in
addition to one metastatic sentinel node had distant metastases to
the liver, found at surgery, and was consequently classified as
Duke’s D (Table 1).
Characterisation of immune cells in sentinel nodes
Single cell suspensions of lymphocytes collected from the tumour,
sentinel and nonsentinel lymph node specimens, and peripheral
blood (PBL), were prepared as described in Material and Methods.
The number of sentinel nodes obtained and average cell yield from
the sentinel node specimens for each patient are given in Table 1.
Cell suspensions were triple stained with antibodies recognising
the very early activation marker CD69 and the surface antigens
CD4 (Figure 1A and B, middle panels) and CD8 (not shown)
followed by flow cytometry analyses (FACS). The lymphocytic gate
was established by gating on forward and side scatter character-
istics. The percentage of CD4
þ and CD8
þ cells in the lymphocytic
gate varied between lymph nodes (Table 1). No significant
correlation was found between the ratio of CD4
þ to CD8
þ cells
and tumour stage or proliferative response (data not shown).
Similar numbers of activated CD4
þCD69
þ lymphocytes were
found both in sentinel and nonsentinel nodes regardless of absence
(Figure 1A middle panel) or presence of metastases (Figure 1B
middle panel). All investigated tumours contained tumour-
infiltrating lymphocytes (TILs) to a various extent. Tumour-
infiltrating lymphocytes were both of the CD4 and CD8 subsets
and the majority presented an activated CD69
þ phenotype. In
peripheral blood activated, CD69
þ lymphocytes were absent (not
shown).
Functional characterisation of lymphocytes
The proliferative responses of the cell populations were char-
acterised by time course
3H-Thymidine incorporation assays using
homogenised denatured autologous tumour cell extracts as antigen
sources (Figure 1A and B right panels and Table 2). TILs did not
proliferate in any of the investigated patients. By contrast, SN
lymphocytes from eight patients classified as Duke’s B proliferated
in an antigen dependent manner against autologous tumour
extract (Figure 1A, right panel and Table 2) with an average peak
proliferation of 2456776473cpm (average7s.e.m.). Peak prolif-
eration was most frequently observed on day 6. In patient no 5,
thymidine incorporation was not performed. SN lymphocytes from
five out of six metastatic nodes (patients no 10–12, 14 and 15)
responded poorly, with an average proliferation of
214171002(average7s.e.m.) (Figure 1B, right panel). From one
Duke’s C patient (no 13) SN lymphocytes proliferated vigorously
when stimulated with autologous tumour extract (30469cpm) and
also exhibited a high spontaneous proliferation (Table 2). In
addition, in two Duke’s B patients the reactivity against a known
colon cancer antigen, carcinoembryonic antigen (CEA) was tested.
However, stimulation of SN lymphocytes with 100mgml
 1 of CEA
did not result in proliferation (data not shown). In nonsentinel
nodes proliferation upon stimulation with tumour extract was not
Duke's B
TIL
AB
SN
LN
C
D
4
CD69
3.4%
17.2%
16.4%
0 0.01 0.1
0 0.010.1
0 0.010.1
c
p
m
Duke's C
TIL
SN
LN
C
D
4
CD69
21.8%
18.8%
19.1%
0 0.010.1
0 0.01 0.1
0 0.01 0.1
c
p
m
0
10000
20000
30000
0
10000
20000
30000
0
10000
20000
30000
0
10000
20000
30000
0
10000
20000
30000
0
10000
20000
30000
Figure 1 Characterisation of lymphocytes. In 15 colon cancer patients, tumour-draining, sentinel lymph nodes were identified by peritumoural injection of
a blue tracer. Specimens from the tumour (CC), sentinel node (SN) and nonsentinel node (LN) and stained with haematoxylin–eosin (left panels) (40 ).
Data from patient no 1 with a Duke’s B tumour (A) and patient no 12 with Duke’s C (B). Arrows indicate the presence of metastatic colon cancer cells in a
sentinel node (B, left panel, SN). Single cell suspensions from the specimens were stained with antibodies against CD4 and the activation marker CD69 and
analysed using flow cytometry (middle panels), the percentage of double positive activated CD4 T-helper cells are indicated in the upper right corner. Cell
suspensions in triplicates were incubated with a 10- and 100-fold dilutions of autologous tumour homogenate in a day 5–7 proliferation assay. Cells were
pulsed 18h before harvesting with 1mCi 3H-Thymidine. Proliferation data from day 5 (A) and day 6 (B), respectively, are shown. Error bars indicate s.e.m.
(right panels).
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sdetected, with the exception of three patients (no 6, 7 and 8)
(Table 2). In PBLs the addition of tumour antigen did not result in
vigorous proliferation in any case, but responses could be seen in
patients no 7, 13 and 14. In the nonsentinel node in patient 11 and
in SN lymphocytes from patient 12, high proliferation indexes were
obtained (Table 2). They represent single-point measurements,
lacking the characteristic dose–response and/or kinetics of
antigen-driven proliferation.
To further investigate the functional state of the lymphocytes, T
cells were stimulated with Con A which by-pass the antigen-
specific activation through the T-cell receptor. TILs were
unresponsive to Con A stimulation, as were SN lymphocytes from
Duke’s C patients no 11–12. SN lymphocytes from the remaining
patients proliferated vigorously, as did PBLs and nonsentinel node
lymphocytes from both C and D patients (Figure 2A and B).
The ability of the lymphocytes to produce IFN-g when
stimulated with antigen or with Con A was investigated in six
patients, no 4, 5, 8, 13–15 (Table 3). Tumour-infiltrating
lymphocytes from Duke’s B patient no 4 secreted high amounts
of IFN-g when stimulated with Con A (717pgml
 1) and five
times the background level upon addition of tumour extract, in
spite of their inability to respond in the proliferation assay.
Tumour-infiltrating lymphocytes from patient 5 (Duke’s B)
(Figure 3) and patient 15 (Duke’s D) did not produce IFN-g when
stimulated with tumour homogenate, nor when they were
stimulated with Con A (data not shown). In patients 8, 13 and
14 (Duke’s C), the amount of TILs obtained, did not suffice for the
IFN-g ELISA.
SN lymphocytes from Duke’s B patients no 4, 5 (Figure 3A) and
8, and from Duke’s C patient no 13 (Figure 4B) secreted IFN-g
4–38 times above background level when stimulated with
autologous tumour homogenate. In patients no 14 and 15 SN
lymphocytes did not produce IFN-g above background, upon
stimulation with tumour homogenate. Lymphocytes from non-
sentinel nodes did not respond with any IFN-g secretion above
background levels (Figure 3A), with the exception of patient no 8,
where the secretion was 30 times the background level. In patients
no 4 and 8 secretory responses of four to five times background
level were seen in PBLs. SN-, nonsentinel lymphocytes and PBLs
displayed a vigorous secretory response when stimulated with Con
A (data not shown).
DISCUSSION
In this study we identify a localised immune response against
autologous tumour extract in patients with colon cancer, by using
an injection technique allowing for the identification of the tumour
draining sentinel node (Figure 1A, right panel, Table 1). SN
lymphocytes have been endogenously sensitised towards tumour-
derived antigens presented by professional antigen presenting cells
and represent a naturally in vivo expanded population of cells that
can be further multiplied and possibly used for immunotherapy.
Proliferation in sentinel nodes, displaying dose dependence and/
or kinetics of antigen dependence, was present in a majority of
patients (Figure 1A, right panel, Table 2). Responses were of
varying magnitude and tended to be weaker or absent in patients
with metastatic sentinel nodes (Table 2 and Figure 1B). We have
recently described proliferative responses against the autologous
tumour in sentinel nodes draining urinary bladder cancers (Marits
et al, 2006), further supporting the immunological value of the
sentinel node detection method. In the three Duke’s B patients no
6–8 dose-dependent proliferation was also detected in nonsentinel
lymph nodes. In patients 6 and 8 these nodes were located on the
predicted lymphatic drainage pathway from the tumour. In patient
7, the exact anatomical location of the investigated nonsentinel
lymph node could not be determined. However, all the 22
investigated lymph nodes in the pathological specimen were
enlarged and displayed histological evidence of immune reactivity.
In six of the patients the IFN-g secretory response was
investigated (Table 3). The IFN-g response correlated closely with
the proliferative responses, with a few exceptions: In patient 4,
TILs did produce IFN-g, but they did not proliferate in response to
the autologous tumour. The same applied to PBLs from this
patient and PBLs from patient 8. This possibly reflects a different
state of effector differentiation in these cells than in lymph node
acquired cells, exemplified by Duke’s C patient no 13. Here, SN
lymphocytes displayed vigorous, spontaneous proliferation which
could be further augmented by the addition of tumour homo-
genate, possibly indicating an ongoing expansion of tumour-
specific effector cells. By contrast, IFN-g secretion was strongly
inducible by antigen stimulation but undetectable in unstimulated
cultures (Figure 4). Factors influencing long-term tumour free
survival following surgical resection of colon cancers are
Table 2 Proliferative responses in lymphocytes from sentinel node, the tumour, nonsentinel node and peripheral blood upon stimulation with autologous
tumour extract
SN TIL LN PBL
Pat nr BG
a Peak
b Peak-BG SI
c BG
a Peak
b Peak-BG SI
c BG
a Peak
b Peak-BG SI
c BG
a Peak
b Peak-BG SI
c
1 9672 26289 16617 2,7 ND 4299 7141 2842 1,7 2496 4731 2235 1,9
2 4049 14559 10510 3,6 382 1485 1103 3,9 818 509 — 0,6 2836 3301 465 1,2
3 1207 15125 13918 12,5 196 1022 826 5,2 2201 3134 933 1,4 553 288 — 0,5
4 1104 43446 42342 39,4 186 546 360 2,9 ND 4570 2536 — 0,6
5N D N D N D N D
6 9810 55430 45620 5,7 1037 2482 1445 2,4 9495 35032 25537 3,7 1592 4245 2653 2,7
7 3555 32141 28586 9,0 ND 2155 79629 77474 37,0 1360 23257 21897 17,1
8 1051 6270 5219 6,0 ND 5400 110655 105255 20,5 2168 3620 1452 1,7
9 449 3283 2833 7,3 ND ND 1092 1377 285 1,3
10 488 1218 730 2,5 ND 313 1109 796 3,5 50 52 2 1,0
11 127 238 111 1,9 262 511 249 2,0 410 3878 3468 9,5
d 645 627 — 1,0
12 341 3848 3507 11,3
d 423 1237 814 2,9 1009 3223 2214 3,2 180 797 617 4,4
13 66901 97370 30469 1,5 ND ND 27333 56664 29331 2,1
14 3328 4506 1178 1,4 ND ND 796 13331 12535 16,7
15 398 248 — 0,6 106 131 25 1,2 215 131 — 0,6 120 126 6 1,1
All values are given in counts per minute (cpm) except the Stimulation Index (SI). SN, sentinel node; TIL, tumour infiltrating lymphocytes; LN, nonsentinel lymph nodes; PBL,
peripheral blood leukocytes. ND¼Not determined. —¼Below background value.
aBG¼Background, proliferation in complete medium, mean value from triplicate.
bPeak¼The highest proliferation upon stimulation with autologous tumour extract, mean value from triplicate.
cSI¼stimulation index¼peak/BG.
dSingle high measurements
without dose–response or antigen dependent kinetics.
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sincompletely understood. Histological parameters indicating a T-
cell mediated immune response in mesocolic lymph nodes have
been found to correlate with increased survival rates (Patt et al,
1975). It is tempting to speculate that the strong immune response
in patient no 13 is a predictor of survival. This will be addressed
when follow-up data from the patients is available.
TILs displayed an activated CD69
þ phenotype, similar to SN
lymphocytes (Figure 1A and B middle panels), but when tested
against autologous tumour antigens (Figure 2A and B right panels)
or Con A (Figure 2A) they did not proliferate. In two metastatic
sentinel nodes, from patients no 11 and 12, the response against
ConA was also blunted, indicating a state of tumour-induced
immunosuppression. Some investigators (Hoon et al, 1987;
O’Sullivan et al, 1996) have observed immunosuppression in
regional lymph nodes also in the absence of lymph node
metastases. This contrasts with our data, where SN lymphocytes
in Duke’s B patients responded adequately to the mitogen ConA
(Figure 2B). This may reflect differences in the biology of the
primary tumour, as indicated by the study by O’Sullivan et al
(1996), who found evidence for immunosuppression in lymph
nodes draining squamous cell carcinomas of the oesophagus but
not in adenocarcinomas. Secretion of immunosuppressive factors
from CRC cell lines has been reported previously (Luo et al, 1997).
Fresh CRC specimens have been shown to express indoleamine
2,3-dioxygenase (IDO), an enzyme, which catalyses tryptophan
degradation. Tryptophan depletion causes proliferative arrest of T
cells and hampers local antitumour immunity in mouse models
(Uyttenhove et al, 2003). In addition, chemokine-mediated
recruitment of CD4
þCD25
þ T regulatory cells to the tumour
bed, has recently been described in ovarial cancer (Curiel et al,
2004). The influence of CD4
þCD25
þ cells on immune responses
against human colon cancers is under investigation in the
laboratory.
Naturally induced, tumour-reactive T cells as measured with
specific cytokine secretion in response to tumour antigens have
been identified in blood in a subset of CRC patients albeit at a low
frequency (Nagorsen et al, 2000). We detected proliferation in
peripheral blood in the three Duke’s C patients no 7, 13 and 14
(Table 2), while PBLs from the other 12 patients were unrespon-
sive. This is consistent with that the majority of these cells have not
encountered tumour antigens and thus the precursor frequency of
T cells in peripheral blood with a specific T-cell receptor
recognising tumour antigen(s) is low.
In a murine system, tumour sensitised but not fully functional,
lymphocytes were identified in tumour draining lymph nodes.
These cells could be converted into effector cells by in vitro
expansion with anti-CD3mAB and IL-2 and were capable of
mediating regression of established metastases following adoptive
transfer (Yoshizawa et al, 1991). In human CRC; adoptive transfer
of in vitro expanded lymph node cells, has been attempted in
patients with advanced metastatic disease (Kim et al, 1999). The
lymph nodes were identified by radioimmuno-guided surgery
(RIGS) utilising a
125I labelled monoclonal antibody against a
mucin expressed by carcinomas, consequently dependent on the
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Figure 2 Proliferative responses against Con A. Tumour infiltrating
lymphocytes (TIL), cells from sentinel node (SN), from nonsentinel lymph
nodes (LN) and peripheral blood leucocytes (PBL), obtained from 15 colon
cancer patients were investigated with
3H-Thymidine incorporation upon
stimulation with 10mgml
 1 of ConA. Data from patient no 2 with a Duke’s B
tumour (A) and patient no 11 with a Duke’s C (B). Error bars indicate s.e.m.
Table 3 Production of IFN-g upon stimulation with autologous tumour extract.
SN TIL LN PBL
Pat nr
BG
a
(pgml
 1)
Peak
b
(pgml
 1)S I
c
BG
a
(pgml
 1)
Peak
b
(pgml
 1)S I
c
BG
a
(pgml
 1)
Peak
b
(pgml
 1)S I
c
BG
a
(pgml
 1)
Peak
b
(pgml
 1)S I
c
4 12 463 38,6 26 120 4,6 8 12 1,5 11 12 1,1
5 30 107 3,7 13 13 1 10 13 1,3 7 7 1,0
8 14 82 5,9 ND ND ND 62 688 11,0 16 93 5,8
13 97 1806 18,6 ND ND ND ND ND ND ND ND ND
14 6 14 2,3 ND ND ND ND ND ND ND ND ND
15 175 94 0,5 24 29 1,2 16 23 1,4 20 17 0,9
SN, sentinel node; TIL, tumour infiltrating lymphocytes; LN, nonsentinel lymph nodes; PBL, peripheral blood leukocytes. ND¼Not determined.
aBG¼Background, secretion of
IFN-g when cultured in complete medium alone, value from pooled triplicates.
bThe highest amount of IFN-g secreted upon stimulation with autologous tumour extract, value
from pooled triplicates.
cSI¼stimulation index¼peak/BG.
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spresence of tumour cells or tumour-derived material in the nodes.
In this study, one patient achieved a partial response and 4 patients
(4/23) minor responses and an overall increase in survival was
observed (Kim et al, 1999), indicating a role for immunotherapy in
colon cancer. In comparison with the present work, we identify the
sentinel node(s), which are the first lymph node(s) to drain the
primary tumour, without the use of radioactivity or depending on
the presence of specific tumour-derived epitopes in the node(s).
In summary, we demonstrate that freshly isolated lymphocytes
from sentinel nodes in patients with established colorectal
carcinoma mount proliferative responses against autologous
tumour extract. These cells have not yet been exposed to the
immunosuppressive milieu of the tumour and constitute an in vivo
expanded source of tumour reactive lymphocytes. Instead of using
TIL or peripheral blood lymphocytes, we propose sentinel node-
derived lymphocytes as a source of enriched tumour reactive T
cells, suitable for adoptive immunotherapy.
ACKNOWLEDGEMENTS
This study was supported by the Swedish Cancer Society, the King
Gustav V’s Jubilee Foundation, the Lions Cancer foundation, the
Lundberg Foundation, the Cancer and Allergy foundation, the
Wiberg Foundation, the Hedlunds foundation and the Selander
foundation.
Tumour homogenate
120
100
80
60
40
20
0
TIL
I
F
N
-

 
(
p
g
 
m
l
−
1
)
SN1 SN2 SN3 LN PBL
ConA
1200
1000
800
600
400
200
0
TIL
I
F
N
-

 
(
p
g
 
m
l
−
1
)
SN1 SN2 SN3 LN PBL
A
B
Figure 3 Stimulation with autologous tumour homogenate elicits IFN-g
production in lymphocytes from sentinel node. In six of 15 patients, IFN-g
secretory responses were investigated with ELISA on culture supernatants.
Tumour infiltrating lymphocytes (TIL), lymphocytes from sentinel nodes
(SN1-3), from nonsentinel node (LN) and in peripheral blood leucocytes
(PBL) from patient no 5, were cultured with medium alone (black bars),
autologous tumour homogenate diluted 1/100 (open bars), 1/10 (grey
bars) (A) or ConA 10mgml
 1 (B). The IFN-g production was measured in
pooled triplicates of supernatants collected at day 5.
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Figure 4 High spontaneous proliferation and specific IFN-g production
upon addition of tumour homogenate in cells from a sentinel node in a case
of Duke’s C. In six of 15 patients, IFN-g secretory responses investigated
with ELISAs on culture supernatants. A single cell suspension from the
sentinel node from patient no 13 was incubated with 10- and 100-fold
dilutions of autologous tumour homogenate in a time course proliferation
assay. Cells were pulsed with 1mCi
3H-Thymidine, 18h before harvesting.
Error bars indicate s.e.m. (A). The corresponding IFN-g production by the
sentinel node acquired lymphocytes was measured in an ELISA on pooled
triplicates of supernatant collected day 7 (B).
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